

From: Sullivan, Nancy E SCC-CBAR

Sent: Friday, October 17, 2003 8:28 AM

To: Tholstrup, Susan C SCC-HSE; Clegg, Patsy M SCC-CHSE-PC

Subject: FW: Progress Report on Benzene Health Research Consortium

Fyi- a reminder when pressure is exerted people can find a way to do it with less money! We still need to stay on top of this, though, to make sure they actually do it within budget!

Nancy Sullivan

VP Aromatics/Phenol

Shell Chemical LP

One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 3084 **Fax:** 8540

Email: nancy.sullivan@shell.com

Internet: <http://www.shell.com/chemicals>

-----Original Message-----

From: Lorraine Twerdok [mailto:Twerdokl@api.org]

Sent: Wednesday, October 15, 2003 4:58 PM

To: Sullivan, Nancy E SCC-CBAR

Subject: FW: Progress Report on Benzene Health Research Consortium

Ms Sullivan -

This message from Mr. Cavaney was inadvertently sent to the wrong contact at Shell. Please accept my apologies for the confusion.

Also, please do not hesitate to contact me with any questions you may have on the information provided in the email.

Thank you,
Lorraine Twerdok

Lorraine E. Twerdok, Ph.D., DABT

Manager, Health Sciences

American Petroleum Institute

1220 L Street, N.W.

Washington, DC 20005

tel: 202-682-8344

fax: 202-682-8031

email: twerdokl@api.org <<mailto:twerdokl@api.org>>

-----Original Message-----

From: Red Cavaney

Sent: Monday, October 13, 2003 12:45 PM

To: 'pillarrj@bp.com'; 'mter@chevrontexaco.com'; 'lee.r.raymond@exxonmobil.com'; 'jim.w.nokes@conocophillips.com'; 'marathonoil.com'

Cc: 'Lynn.Elsenhans@shell.com'; 'jjmulva@conocophillips.com'; 'mbitter@chevrontexaco.com'; Red Cavaney; Charles Sandler; Howard Feldman; Harry Ng; Brenda Hargett; Lorraine Twerdok

Subject: Progress Report on Benzene Health Research Consortium

I am pleased to attach a Progress Report from the Benzene Health Research Consortium, in which they state their Oversight Committee "has unanimously agreed that a scientifically rigorous, unique research project to further the current understanding of the human health effects of benzene could be executed at this funding level (\$20,884,000+\$200,000) without sacrificing the integrity of program results."

SHELL-MCCLURG-065964

API staff will follow through with converting this commitment to the new contract documentation and appropriate new billings, as well as continue its contract administration and coordination role.

An outcome which provides for the continuation of this important research would have not been achievable without the incredible patience and support you have given, and for that I am hugely grateful...many thanks.....red cavaney

From: Paula Podhasky [Podhaskyp@api.org]
Sent: Thursday, January 16, 2003 9:55 AM
To: Patsy Clegg (E-mail)
Subject: BHRC invoice
per your request
pp

	A	B	C	D	E	F
1			Original Cost	Approved	Unapproved	Approved
2	Item		Estimate (Jan. 2001)	Revised Cost Estimate (Dec. 2001)	Changes API not approved (June 2003)	11 NOV 03 OC mtg
3	AHSciences Case-Control Study		\$1,595,000	\$2,283,095	\$2,283,095	\$2,283,095
4	DP & ME Studies (UCHSC)		\$13,665,017	\$15,258,017	\$15,258,000	\$14,508,000
5	Irons(T & E)		\$1,253,428	\$1,253,428	\$1,597,273	\$1,413,428
6	Fudan University		\$165,700	\$190,555	\$661,000	\$230,000
7		Total Research Costs	\$16,679,145	\$18,985,095	\$19,799,368	\$18,434,523
8	Scientific Review Panel			\$648,000	\$551,736	\$300,000
9	Ethics Review Panel			\$216,000	\$192,000	\$64,000
10	External Pathology & Cytogenetics Workgroups(Cost in UC cost)			\$130,000	\$0	\$0
11		Total Panel Costs	\$450,000	\$994,000	\$743,736	\$364,000
12	API Seed Monies		\$500,000	\$0	\$0	\$0
13	Outside Counsel			\$500,000	\$100,576	\$100,000
14	Public Affairs		\$1,000,000	\$1,000,000	\$960,600	\$550,000
15	QA/QC Activities			\$225,000	\$100,000	\$100,000
16	UCHSC Interest					(\$100,000)
17	contingency		\$190,855	\$0	\$0	\$390,272
18		Miscellaneous Costs	\$1,690,855	\$1,725,000	\$1,161,176	\$1,040,272
19		Subtotal	\$18,820,000	\$21,704,095	\$21,704,280	\$19,838,795
20		API Admin.	\$941,000	\$1,085,205	\$1,085,019	\$1,245,205
21	GRAND TOTAL		\$19,761,000	\$22,789,300	\$22,789,299	\$21,084,000
22				UCHSC interest		
23						
24						
25						
26	Notes by API					
27	Notes/Assumptions for Dec. 2001 revised budget:					
28		- The total research costs have changed as a result of the				
29		- Panel costs assume that there will be only one face-to-face				
30		meeting for each panel each year.				
31						
32		- QA/QC costs are based on an assumption of \$45,000 per year				

From: Lorraine Twerdok [Twerdokl@api.org]
Sent: Wednesday, November 12, 2003 11:30 AM
To: Benzene OC listserve (E-mail)
Subject: BHRC budget 11-10-03.xls

New, approved budget and explanation of API accounting procedures and definitions for API expense categories - as requested.

Benzene Health Research Consortium
4Q03 Financial Report Overview

	A	B	C	D	E	F	G	H
1								
2	NOTE: budgets forward adjusted based on approved \$21,084,000 total, per 11Nov2003 OC meeting.							
3								
4	RESEARCH PROGRESS:							
5								
6	AML and NHL Epidemiology Study: as of December, 2003 case accrual rates are within predicted range, with 66 NHL and 42 AML cases, for a total of 108 accepted cases (see Case Accrual table)							
7	case referral steadily increasing since 3Q04.							
8								
9								
10	Disease Progression & Molecular Epidemiology: 90% concordance between Clinical Lab (JCML) case evaluation & secondary pathology review (50% concordance with hospital case referrals).							
11								
12	Case Accrual: AML, NHL, AA & MDS above 4Q03 projections. No benzene poisoning cases.							
13								
14								
15	Exposure Assessment: DP & ME Exposure Assessment operational; CC exposure recreation team reorganized and further trained to enhance assessment rate & quality.							
16								
17	External Review Panels: Dr. Rice is actively recruiting a replacement for Dr. Brody, who resigned as ERP Chair 4Q03.							
18								
19	EXPENSE DISCUSSION:							
20								
21	Fund Balance at API 4Q03 =			\$5,143,568				
22								
23	NEW! 'exec summ' worksheet for the big picture							
24								
25								
26	Overall Budget: program is under budget, using the current budget estimates. Need to revise SRP/ERP projections (see below), and get revised cost estimates for UCHSC and Irons' Field Expenses.							
27	UCHSC: Unspent amount = \$1,472,277. (-\$523,807) reduction in expense adjustment made to correct 3Q03 unintentional error of double counting 2001 expenses. A detail sheet has been added for							
28	subcontractor expenses. API is working to recoup interest earned on unspent grant funds, however, UCHSC is resistant, and no provisions were in original grant. Amendment #2 to be completed 10/03							
29	Technical Budget WG approval, \$48,839 attributed to UCHSC in 3Q03 Report has been reallocated to Contingency: \$25,000 pre-consortium grant in 2001; \$3,600 for IRB Review in 2002; \$20,239							
30	Irons Field Expenses: current prepaid funds nearly depleted; \$27,216 prepaid funds remaining; disbursement requested in 1Q04. +\$114,289 additional expense adjustment made to 4Q03 report to							
31	AHS: over budget with negative variance of (-\$52,477); Dr. Wong states project will end "on budget".							
32	Fudan University: under budget with positive variance of \$81,425							
33	SRP/ERP: under budget with positive variance of \$198,778.							
34	Communications (APCO): 'on budget' after adjustments made to reflect budget reduction							
35	Outside Legal Council: 'on budget' after adjustments made to reflect budget reduction							
36	QA/QC: under budget, no contract in place							
37								
38	API Administrative Costs: over budget with negative variance of (-\$65,484). Overbudget due to unbudgeted Annual meeting expenses and higher than anticipated staff time required for annual M							
39	planning, contract/budget reviews and development of detailed financial report format.							
40								
41	FORWARD GUIDANCE:							
42	Review report to determine payment schedule for consortium agreement amendment (what year?)							
43								
44	Collect Marathon payment. Collect second half of 2003 invoice payment from ExxonMobil and Shell							
45								
46	Two budget areas are currently over budget, and will require close monitoring:							
47		AHS						
48		API administrative costs						

	I	J
1		
2		
3		
4		
5		
6	p). Rate of	
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26	ses	
27	or UCHSC	
28	Q04. With	
29	9 for EMBSI	
30	correct	
31		
32		
33		
34		
35		
36		
37		
38	eting	
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		

Benzene Health Research Consortium
4Q03 Financial Report Overview

	A	B	C	D	E	F	G	H
49								
50								
51	It is recommended that SRP/ERP budget projections be adjusted to make the report a more useful tool. Currently carrying a large positive variance, with unrealistically low projected budgets.							
52								
53	Get Fudan University contract in place.							
54								
55	Get new contract in place for Irons field expenses.							
56								
57	Need revised budget and budget projections for UCHSC grant, Irons Field Expenses and AHS. Need to reconcile UCHSC statement - they have a \$105 error.							
58								
59	Technical Budget Work Group Acceptance: 4/9/04							
60	Oversight Committee Acceptance:							
61	Posted to website:							
62								
63	LT 4/13/04							
64	BJ 4/12/04							

Benzene Health Research Consortium
4Q03 Financial Report Overview

	I	J
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		
61		
62		
63		
64		

Benzene Health Research Consortium
Approved Program Budget
4Q03 Financial Report

	A	B	C	D	E	F
1			Original Cost	Approved	Unapproved	Approved
2	Item		Estimate (Jan. 2001)	Revised Cost Estimate (Dec. 2001)	Changes API not approved (June 2003)	11 NOV 03 OC mtg
3	AHSciences Case-Control Study		\$1,595,000	\$2,283,095	\$2,283,095	\$2,283,095
4	DP & ME Studies (UCHSC)		\$13,665,017	\$15,258,017	\$15,258,000	\$14,508,000
5	Irons(T & E)		\$1,253,428	\$1,253,428	\$1,597,273	\$1,413,428
6	Fudan University		\$165,700	\$190,555	\$661,000	\$230,000
7	Total Research Costs		\$16,679,145	\$18,985,095	\$19,799,368	\$18,434,523
8	Scientific Review Panel			\$648,000	\$551,736	\$300,000
9	Ethics Review Panel			\$216,000	\$192,000	\$64,000
10	External Pathology & Cytogenetics Workgroups(Cost in UC cost)			\$130,000	\$0	\$0
11	Total Panel Costs		\$450,000	\$994,000	\$743,736	\$364,000
12	API Seed Monies		\$500,000	\$0	\$0	\$0
13	Outside Counsel			\$500,000	\$100,576	\$100,000
14	Public Affairs		\$1,000,000	\$1,000,000	\$960,600	\$550,000
15	QA/QC Activities			\$225,000	\$100,000	\$100,000
16	UCHSC Interest					(\$100,000)
17	contingency		\$190,855	\$0	\$0	\$390,272
18	Miscellaneous Costs		\$1,690,855	\$1,725,000	\$1,161,176	\$1,040,272
19	Subtotal		\$18,820,000	\$21,704,095	\$21,704,280	\$19,838,795
20	API Admin.		\$941,000	\$1,085,205	\$1,085,019	\$1,245,205
21	GRAND TOTAL		\$19,761,000	\$22,789,300	\$22,789,299	\$21,084,000
22						
23						
24						
25						
26	Notes by API					
27	Notes/Assumptions for Dec. 2001 revised budget:					
28		- The total research costs have changed as a result of the				
29		- Panel costs assume that there will be only one face-to-face				
30		meeting for each panel each year.				
31						
32	LT 4/7/04					

Benzene Health Research Consortium
Executive Summary
4Q03 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1															
2															
3			Actuals					Budget (actual + projected income & expens							
4			Inception					Cumulative							
5			Thru	Actuals				Actuals							
6			December	Jan - Dec		Program		Inception							
7	<u>Cost Centers</u>	<u>Project #</u>	2002	2003		to Date		Thru 2003		2004		2005		2006	
8															
9	<u>Income</u>		\$ 10,540,824	\$ 4,716,451		\$ 15,257,275		\$ 15,257,275		\$ 1,485,875				\$ 100,000	
10															
11															
12	<u>Cost Centers</u>														
13	UCHSC*	X8105	7,564,598	(48,839)		7,515,759		7,515,759		1,748,061		1,748,060		1,748,060	
14	Irons-Field Expense**	X8106	539,486	-		539,486		539,486		222,032		222,032		222,030	
15	Applied Health Sciences	X8107	571,734	432,791		1,004,525		1,004,525		393,361		441,867		449,985	
16	Fudan University	X8108	15,470	16,511		31,981		31,981		29,151		29,148		29,148	
17	Scientific & Ethics Panels	X8109	23,795	59,059		82,854		82,854		20,608		20,592		20,592	
18	Communications	X8103	240,738	50,128		290,866		290,866		60,001		60,000		60,000	
19	Outside Legal Counsel	X8104	13,565	19,643		33,208		33,208		16,698		16,698		16,698	
20	QA/QC Support	X8110	-	-		-		-		25,000		25,000		25,000	
21	API Administrative	X8100	265,745	300,444		566,189		566,189		311,000		144,500		144,500	
22	Contingency		-	48,839		48,839		48,839		-		341,433		-	
23															
24	Total Expenses		\$ 9,235,131	\$ 878,576		\$ 10,113,707		\$ 10,113,707		\$ 2,825,912		\$ 3,049,330		\$ 2,716,013	
25															
26	Fund Balance		\$ 1,305,694	\$ 3,837,875		\$ 5,143,568				\$ 3,803,531		\$ 754,201		(\$1,861,812)	
27															
28															
29	blue is projected fund balanced to project														
30	* amount disbursed by API; \$1,472,277														
31	** amount disbursed by API; \$27,216														
32	unspent and in Irons' Field expense bank														
33	LT 4/14/04														
34															
35															
36															
37															
38															

Benzene Health Research Consortium
Executive Summary
4Q03 Financial Report

	P	Q	R	S
1				
2				
3	es)			
4				
5				
6			Total	Total adj.
7	2007		Program	w/variance
8				
9	\$ -		\$ 16,843,150	\$ 16,843,150
10				
11				
12				
13	1,748,060		14,508,000	14,508,000
14	222,028		1,427,608	1,413,428
15	45,833		2,335,571	2,283,094
16	29,148		148,576	230,001
17	20,576		165,222	364,000
18	79,135		550,002	550,000
19	16,698		100,000	100,000
20	25,000		100,000	100,000
21	144,500		1,310,689	1,245,205
22	-		390,272	390,272
23				
24	\$ 2,330,978		\$ 21,035,940	\$ 21,184,000
25				
26	(\$4,192,790)			
27				
28				
29				
30				
31	Income Detail			
32	sponsors		\$16,500,000	
33	MAP seed		\$15,000	
34	MAP contrib.		\$200,000	
35	UCHSC int.		\$100,000	
36	API interest		\$28,148	
37				
38	TOTAL		\$16,843,148	

Benzene Health Research Consortium
Case Accrual 4Q03 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U
1	Case Accrual (Study Goal)	2003			2004				2005				2006				2007				TOTALS
2		1st & 2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	
3	AML (450 total)																				
4	Cases Projected			35	35	35	35	35	35	35	35	35	35	35	35	35					
5	Actual cases			42																	
6	CurrentVariance																				
7	Cumm Variance																				
8	NHL (120/yr)																				
9	Cases Projected			35	35	35	35	35	35	35	35	35	35	35	35	35					455
10	Actual cases			66																	66
11	CurrentVariance																				0
12	Cumm Variance																				0
13	AA (50/yr)																				
14	Cases Projected			12	13	12	13	12	13	12	13	12	13	12	13	12					162
15	Actual cases			17																	17
16	CurrentVariance																				0
17	Cumm Variance																				0
18	MDS (60/yr)																				
19	Cases Projected			15	15	15	15	15	15	15	15	15	15	15	15	15					195
20	Actual cases			26																	26
21	CurrentVariance																				0
22	Cumm Variance																				0
23	Benzene Poisoning (10/yr)																				
24	Cases Projected			3	2	3	2	3	2	3	2	3	2	3	2	3					33
25	Actual cases			0																	0
26	CurrentVariance																				0
27	Cumm Variance																				0
28	TOTALS																				
29	Cases Projected																				845
30	Actual cases																				109
31																					
32																					
33																					
34	LT 4/14/04																				
35	BJ 4/12/04																				

Benzene Health Research Consortium
Cash Flow Statement 4Q03 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R
1		2000	2001	2002		2003				2004			2005				2006	
2		1st - 4th Qtr.	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.
3	INCOME																	
4	Income for Reporting Period	\$60,246	\$2,113,132	\$9,367,446	\$448,024	\$3,186	\$4,265,241	\$1,485,875	\$5,000	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$100,000	\$0
5	Income, Cumulative	\$60,246	\$2,173,378	\$10,540,824	\$10,988,848	\$10,992,034	\$15,257,275	\$16,743,149	\$16,748,149	\$16,748,149	\$16,748,149	\$16,748,149	\$16,748,149	\$16,748,149	\$16,748,149	\$16,748,149	\$16,848,149	\$16,848,149
6	EXPENSE																	
7	Actual API Expenses	\$24,600	\$1,571,301	\$7,639,230	\$310,235	\$258,097	\$310,244	\$269,464	\$1,096,995	\$269,463	\$1,096,994	\$238,072	\$1,065,620	\$245,589	\$1,065,620	\$240,118	\$1,067,641	\$247,617
8	Expense, Cumulative	\$24,600	\$1,595,901	\$9,235,131	\$9,545,366	\$9,803,463	\$10,113,707	\$10,383,171	\$11,480,166	\$11,749,628	\$12,846,622	\$13,084,694	\$14,150,315	\$14,395,903	\$15,461,523	\$15,701,641	\$16,769,282	\$17,016,898
9	INCOME LESS EXPENSE																	
10	Reporting Period	\$35,646	\$541,831	\$728,216	\$137,789	(\$254,911)	\$3,954,997	\$1,216,411	(\$1,091,995)	(\$269,463)	(\$1,096,994)	(\$238,072)	(\$1,065,620)	(\$245,589)	(\$1,065,620)	(\$240,118)	(\$967,641)	(\$247,617)
11	Cumulative	\$35,646	\$577,477	\$1,305,693	\$1,443,482	\$1,188,571	\$5,143,568	\$6,359,978	\$5,267,984	\$4,998,521	\$3,901,527	\$3,663,455	\$2,597,835	\$2,352,246	\$1,286,626	\$1,046,508	\$78,868	(\$168,749)
12																		
13		NOTE:	\$5,143,568	in bank at API														
14	blue designates projected income or expense																	
15																		
16	LT 4/7/04																	

Benzene Health Research Consortium
Cash Flow Statement 4Q03 Financial Report

	S	T	U	V	W	X
1	2007					TOTALS
2	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	
3						
4	\$0	\$0	\$0	\$0	\$0	\$16,848,149
5	\$16,848,149	\$16,848,149	\$16,848,149	\$16,848,149	\$16,848,149	
6						
7	\$1,067,659	\$178,237	\$959,946	\$139,889	\$959,931	\$20,322,559
8	\$18,084,557	\$18,262,794	\$19,222,739	\$19,362,628	\$20,322,559	
9						
10	(\$1,067,659)	(\$178,237)	(\$959,946)	(\$139,889)	(\$959,931)	
11	(\$1,236,408)	(\$1,414,645)	(\$2,374,590)	(\$2,514,479)	(\$3,474,410)	
12						
13						
14						
15						
16						

**Benzene Health Research Consortium
Program Expense Summary 4Q03 Financial Report**

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P
2	Cost Centers	2000 1st - 4th Qtr.	2001 1st - 4th Qtr.	2002 1st - 4th Qtr.	2003 1st & 2nd Qtr.	2003 3rd Qtr.	4th Qtr.	1st Qtr.	2004 2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2005 2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.
3	UCHSC															
4	Disbursed		1,225,000	6,339,598	0	0	(48,839)	0	874,031	0	874,030	0	874,030	0	874,030	0
5	Budgeted	0	648,390	3,969,140	1,230,711	0	2,039,466	0	827,532	0	827,532	0	827,532	0	827,532	0
6	Actual expense	0	523,807	3,248,834	1,717,169	0	553,672	0	0	0	0	0	0	0	0	0
7	Current/Variance	0	124,583	720,306	(486,458)	0	1,485,794	0	827,532	0	827,532	0	827,532	0	827,532	0
8	Cumm Variance	0	124,583	844,889	332,137	332,137	1,813,804	1,813,804	2,631,500	2,631,500	3,449,196	3,449,196	4,266,892	4,266,892	5,084,588	5,084,588
9	Irons - Field Expenses															
10	Disbursed		145,763	393,723												
11	Budgeted	0	3,200	259,060	138,359	69,179	55,508	55,508	55,508	55,508	55,508	55,508	55,508	55,508	55,508	55,508
12	Actual expense	0	3,157	195,549	89,577	54,382	169,606	0	0	0	0	0	0	0	0	0
13	Current/Variance	0	43	63,511	48,782	14,797	(114,098)	55,508	55,508	55,508	55,508	55,508	55,508	55,508	55,508	55,508
14	Cumm Variance	0	43	63,554	112,336	127,133	13,035	68,543	124,051	179,559	235,067	290,575	346,083	401,591	457,099	512,607
15	Applied Health Sciences															
16	Budgeted	0	84,025	435,513	216,256	108,128	108,128	98,340	98,340	98,340	98,340	110,467	110,467	110,467	110,467	112,496
17	Actual expense	0	136,329	435,406	140,665	149,389	142,737	0	0	0	0	0	0	0	0	0
18	Current/Variance	0	(52,304)	107	75,591	(41,261)	(34,609)	98,340	98,340	98,340	98,340	110,467	110,467	110,467	110,467	112,496
19	Cumm Variance	0	(52,304)	(52,197)	23,394	(17,868)	(52,477)	45,86								

Benzene Health Research Consortium
Program Expense Summary 4Q03 Financial Report

	Q	R	S	T	U	V	W	X
1	2006			2007				TOTALS
2	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	
3								
4	874,030	0	874,030	0	874,030	0	874,030	14,568,000
5	827,539	0	827,542	0	827,542	0	827,542	14,568,000
6	0	0	0	0	0	0	0	6,043,482
7	827,539	0	827,542	0	827,542	0	827,542	827,542
8	5,902,284	5,902,284	6,719,980	6,719,980	7,537,676	7,537,676	8,355,372	8,464,518
9								
10								
11	55,508	55,507	55,507	55,507.0	55,507	55,507	55,507	1,413,428
12	0	0	0	0	0	0	0	512,270
13	55,508	55,507	55,507	55,507	55,507	55,507	55,507	679,129
14	568,115	623,622	679,129	734,636	790,143	845,650	901,157	901,157
15								
16	112,496	112,496	112,496	45,833	0	0	0	2,283,095
17	0	0	0	0	0	0	0	1,004,526
18	112,496	112,496	112,496	45,833	0	0	0	0
19	1,007,744	1,120,240	1,232,736	1,278,569	1,278,569	1,278,569	1,278,569	1,278,569
20								
21	7,287	7,287	7,287	7,287	7,287	7,287	7,287	230,000
22	0	0	0	0	0	0	0	31,981
23	7,287	7,287	7,287	7,287	7,287	7,287	7,287	7,287
24	154,298	161,585	168,872	176,159	183,446	190,733	198,020	198,020
25								
26	5,136	5,152	5,152	5,152	5,152	5,136	5,136	364,000
27	0	0	0	0	0	0	0	82,854
28	5,136	5,152	5,152	5,152	5,152	5,136	5,136	5,136
29	250,266	255,418	260,570	265,722	270,874	276,010	281,146	281,146
30								
31	15,000	15,000	15,000	19,783	19,783	19,784	19,784	550,000
32	0	0	0	0	0	0	0	290,866
33	15,000	15,000	15,000	19,783	19,783	19,784	19,784	259,134
34	149,999	164,999	179,999	199,782	219,566	239,350	259,134	259,134
35								
36	4,175	4,175	4,175	4,175	4,175	4,175	4,175	100,000
37	0	0	0	0	0	0	0	33,208
38	4,175	4,175	4,175	4,175	4,175	4,175	4,175	66,792
39	41,745	45,920	50,084	54,269	58,443	62,618	66,792	66,792
40								
41	6,250	6,250	6,250	6,250	6,250	6,250	6,250	100,000
42	0	0	0	0	0	0	0	0
43	6,250	6,250	6,250	6,250	6,250	6,250	6,250	100,000
44	62,500	68,750	75,000	81,250	87,500	93,750	100,000	100,000
45								
46	0	0	0	0	0	0	0	390,272
47	0	0	0	0	0	0	0	48,839
48	0	0	0	0	0	0	0	0
49	341,433	341,433	341,433	341,433	341,433	341,433	341,433	341,433
50								
51	34,250	41,750	34,250	34,250	34,250	41,750	34,250	1,245,205
52	0	0	0	0	0	0	0	541,589
53	34,250	41,750	34,250	34,250	34,250	41,750	34,250	679,016
54	458,516	500,266	534,516	568,766	603,016	644,766	679,016	703,616
55	2006			2007				
56	1,067,641	247,617	1,067,659	178,237	959,946	139,889	959,931	21,184,000
57	0	0	0	0	0	0	0	8,614,215
58	1,067,641	247,617	1,067,659	178,237	959,946	139,889	959,931	12,569,785
59	9,016,508	9,264,125	10,331,783	10,510,020	11,469,966	11,609,854	12,569,785	12,569,785
60	2006			2007				
61	17,630,723	17,878,339	18,945,998	19,124,235	20,084,180	20,224,069	21,184,000	21,184,000
62	8,614,215	8,614,215	8,614,215	8,614,215	8,614,215	8,614,215	8,614,215	8,614,215
63	9,016,508	9,264,125	10,331,783	10,510,020	11,469,966	11,609,854	12,569,785	12,569,785
64								
65								
66								

**Benzene Health Research Consortium
UCHSC Grant 4Q03 Financial Report**

	A	B	C	D
1	UCHSC	2001	2002	
2	Cost Centers	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.
3	Grant Payments			
4	Disbursed	1,225,000	6,339,598	0
5	Personnel			
6	Budgeted	172,140	573,160	331,316
7	Actual expense	172,140	714,688	314,703
8	CurrentVariance	0	-141,528	16,613
9	Cumm Variance	0	-141,528	-124,915
10	Operating Expenses			
11	Budgeted	13,131	378,462	198,373
12	Actual expense	12,177	301,522	158,850
13	CurrentVariance	954	76,940	39,523
14	Cumm Variance	954	77,894	117,417
15	Subcontracts			
16	Budgeted	123,629	1,795,030	549,014
17	Actual expense	0	1,025,372	845,860
18	CurrentVariance	123,629	769,658	-296,846
19	Cumm Variance	123,629	893,287	596,441
20	Travel			
21	Budgeted	0	23,947	11,340
22	Actual expense	0	8,647	346
23	CurrentVariance	0	15,300	10,994
24	Cumm Variance	0	15,300	26,294
25	Equipment			
26	Budgeted	\$291,568	\$919,845	\$0
27	Actual expense	\$291,568	\$899,842	\$274,508
28	CurrentVariance	\$0	\$19,003	(\$274,508)
29	Cumm Variance	\$0	\$19,003	(\$255,505)
30	Indirect			
31	Budgeted	\$47,922	\$279,896	\$140,668
32	Actual expense	\$47,922	\$298,963	\$122,902
33	CurrentVariance	(\$0)	(\$19,067)	\$17,766
34	Cumm Variance	(\$0)	(\$19,067)	(\$1,301)
35	TOTALS	2001	2002	
36	Budgeted	\$648,390	\$3,969,140	\$1,230,711
37	Actual expense	\$523,807	\$3,248,834	\$1,717,169
38	CurrentVariance	\$124,583	\$720,306	(\$486,458)
39	Cumm Variance	\$124,583	\$844,889	\$332,137
40	CUMULATIVE TOTALS	2001	2002	
41	Budgeted	\$648,390	\$4,617,530	\$5,948,241
42	Expense	\$523,807	\$3,772,641	\$5,489,810
43	Variance	\$124,583	\$844,889	\$358,431
44				
45	Blue: future cumulative variance has no meaning until Expense entered.	Note: Actual expenses are taken from UC Office of Grants & Contracts report.		
46				
47		Amt. paid UCHSC to date:		\$7,515,759
48	LT 4/14/04	Amt. expensed to date:		\$6,043,482
49	BJ 4/9/04	Amt. In UCHSC bank acct:		\$1,472,277

**Benzene Health Research Consortium
UCHSC Grant 4Q03 Financial Report**

	E	F	G	H	I
1	2003			2004	
2	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.
3					
4	0	-48,839	0	874,031	0
5					
6	0	293,007	0	195,778	0
7	0	58,188	0	0	0
8	0	234,819	0	195,778	0
9	-124,915	109,904	109,904	305,682	305,682
10					
11	0	259,003	0	195,773	0
12	0	150,657	0	0	0
13	0	108,346	0	195,773	0
14	117,417	225,763	225,763	421,536	421,536
15					
16	0	988,733	0	286,990	0
17	0	565,870	0	0	0
18	0	422,863	0	286,990	0
19	596,441	1,019,304	1,019,304	1,306,294	1,306,294
20					
21	0	4,127	0	9,836	0
22	0	0	0	0	0
23	0	4,127	0	9,836	0
24	26,284	30,421	30,421	40,257	40,257
25					
26	\$0	\$350,000	\$0	\$48,050	\$0
27	\$0	(\$274,568)	\$0	\$0	\$0
28	\$0	\$624,568	\$0	\$48,050	\$0
29	(\$255,505)	\$369,063	\$369,063	\$417,113	\$417,113
30					
31	\$0	\$144,596	\$0	\$91,105	\$0
32	\$0	\$53,525	\$0	\$0	\$0
33	\$0	\$91,071	\$0	\$91,105	\$0
34	(\$1,301)	\$89,770	\$89,770	\$180,875	\$180,875
35	2003			2004	
36	\$0	\$2,039,466	\$0	\$827,532	\$0
37	\$0	\$553,672	\$0	\$0	\$0
38	\$0	\$1,485,784	\$0	\$827,532	\$0
39	\$332,137	\$1,813,804	\$1,813,804	\$2,631,500	\$2,631,500
40	2003			2004	
41	\$5,848,241	\$7,887,707	\$7,887,707	\$8,715,239	\$8,715,239
42	\$5,489,810	\$6,043,482	\$6,043,482	\$6,043,482	\$6,043,482
43	\$358,431	\$1,844,225	\$1,844,225	\$2,671,757	\$2,671,757
44					
45				UCHSC statement error for travel, off by +\$105	
46					
47	(Adjusted 4Q03: \$48,839 attributed to UCHSC in 3Q03 Report has been reallocated to Contingency: \$25,000 <i>pre-consortium grant in 2001</i> ; \$3,600 for IRB Review in 2002; \$20,239 for EMBSI "feasibility study" in 2002)				
48	(Adjusted 4Q03: 2001 costs had been double expensed in 2002 column; (-\$523,807) adjustment made in 4Q03)				
49					

Benzene Health Research Consortium
UCHSC Grant 4Q03 Financial Report

	J	K	L	M	N	O	P	Q	R	S	T	U	V	W
1	2005				2006				2007				TOTALS	
2	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	
3														
4	874,030	0	874,030	0	874,030	0	874,030	0	874,030	0	874,030	0	874,030	14,508,000
5														
6	195,778	0	195,778	0	195,778	0	195,778	0	195,778	0	195,778	0	195,778	2,935,847
7	0	0	0	0	0	0	0	0	0	0	0	0	0	1,259,719
8	195,778	0	195,778	0	195,778	0	195,778	0	195,778	0	195,778	0	195,778	195,778
9	501,460	501,460	697,238	697,238	893,016	893,016	1,088,794	1,088,794	1,284,572	1,284,572	1,480,350	1,480,350	1,676,128	1,676,128
10														
11	195,773	0	195,773	0	195,773	0	195,773	0	195,773	0	195,773	0	195,773	2,415,153
12	0	0	0	0	0	0	0	0	0	0	0	0	0	623,206
13	195,773	0	195,773	0	195,773	0	195,773	0	195,773	0	195,773	0	195,773	195,773
14	617,309	617,309	813,082	813,082	1,008,855	1,008,855	1,204,628	1,204,628	1,400,401	1,400,401	1,596,174	1,596,174	1,791,947	1,791,947
15														
16	286,990	0	286,990	0	286,990	0	286,990	0	286,990	0	286,990	0	286,990	5,752,326
17	0	0	0	0	0	0	0	0	0	0	0	0	0	2,437,102
18	286,990	0	286,990	0	286,990	0	286,990	0	286,990	0	286,990	0	286,990	286,990
19	1,593,284	1,593,284	1,880,274	1,880,274	2,167,264	2,167,264	2,454,254	2,454,254	2,741,244	2,741,244	3,028,234	3,028,234	3,315,224	3,315,224
20														
21	9,836	0	9,836	0	9,836	0	9,843	0	9,846	0	9,846	0	9,846	118,139
22	0	0	0	0	0	0	0	0	0	0	0	0	0	8,983
23	9,836	0	9,836	0	9,836	0	9,843	0	9,846	0	9,846	0	9,846	9,846
24	50,093	50,093	59,929	59,929	69,765	69,765	79,608	79,608	89,454	89,454	99,300	99,300	109,146	109,146
25														
26	\$48,050	\$0	\$48,050	\$0	\$48,050	\$0	\$48,050	\$0	\$48,050	\$0	\$48,050	\$0	\$48,050	\$1,944,613
27	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$1,191,150
28	\$48,050	\$0	\$48,050	\$0	\$48,050	\$0	\$48,050	\$0	\$48,050	\$0	\$48,050	\$0	\$48,050	\$48,050
29	\$465,163	\$465,163	\$513,213	\$513,213	\$561,263	\$561,263	\$609,313	\$609,313	\$657,363	\$657,363	\$705,413	\$705,413	\$753,463	\$753,463
30														
31	\$91,105	\$0	\$91,105	\$0	\$91,105	\$0	\$91,105	\$0	\$91,105	\$0	\$91,105	\$0	\$91,105	\$1,341,922
32	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$523,312
33	\$91,105	\$0	\$91,105	\$0	\$91,105	\$0	\$91,105	\$0	\$91,105	\$0	\$91,105	\$0	\$91,105	\$91,105
34	\$271,980	\$271,980	\$363,085	\$363,085	\$454,190	\$454,190	\$545,295	\$545,295	\$636,400	\$636,400	\$727,505	\$727,505	\$818,610	\$818,610
35	2005				2006				2007					
36	\$827,532	\$0	\$827,532	\$0	\$827,532	\$0	\$827,539	\$0	\$827,542	\$0	\$827,542	\$0	\$827,542	\$14,508,000
37	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$6,043,482
38	\$827,532	\$0	\$827,532	\$0	\$827,532	\$0	\$827,539	\$0	\$827,542	\$0	\$827,542	\$0	\$827,542	\$827,542
39	\$3,449,196	\$3,449,196	\$4,266,892	\$4,266,892	\$5,084,588	\$5,084,588	\$5,902,284	\$5,902,284	\$6,719,980	\$6,719,980	\$7,537,676	\$7,537,676	\$8,355,372	\$8,464,518
40	2005				2006				2007					
41	\$9,542,771	\$9,542,771	\$10,370,303	\$10,370,303	\$11,197,835	\$11,197,835	\$12,025,374	\$12,025,374	\$12,852,916	\$12,852,916	\$13,680,458	\$13,680,458	\$14,508,000	\$14,508,000
42	\$6,043,482	\$6,043,482	\$6,043,482	\$6,043,482	\$6,043,482	\$6,043,482	\$6,043,482	\$6,043,482	\$6,043,482	\$6,043,482	\$6,043,482	\$6,043,482	\$6,043,482	\$6,043,482
43	\$3,499,289	\$3,499,289	\$4,326,821	\$4,326,821	\$5,154,353	\$5,154,353	\$5,981,892	\$5,981,892	\$6,809,434	\$6,809,434	\$7,636,976	\$7,636,976	\$8,464,518	\$8,464,518
44														
45														
46														
47														
48														
49														

Benzene Health Research Consortium
UCHSC Subcontract 4Q03 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U
1	UCHSC	2001	2002	2003		2004		2005		2006		2007									
2	Subcontracts	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.		3rd & 4th Qtr.		1st & 2nd Qtr.		3rd & 4th Qtr.		1st & 2nd Qtr.		3rd & 4th Qtr.		1st & 2nd Qtr.		3rd & 4th Qtr.		1st & 2nd Qtr.	
3	Fudan University																				
4	Actual expense	0	0	411,935		468,341		0		0		0		0		0		0		0	
5	IPHSC																				
6	Actual expense	0	0	8,339		27,496		0		0		0		0		0		0		0	
7	SMCDGP																				
8	Actual expense	0	0	45,563		24,766		0		0		0		0		0		0		0	
9	EMBSI																				
10	Actual expense	0	0	372,725		0		0		0		0		0		0		0		0	
11	Children's Hospital Cincinnati																				
12	Actual expense	0	0	7,298		45,267		0		0		0		0		0		0		0	
13	TOTALS	2001	2002	2003		2004		2005		2006		2007									
14	Actual expense	\$0	\$1,025,372	\$845,860		\$565,870		\$0		\$0		\$0		\$0		\$0		\$0		\$0	
15																					
16		*Actual expenses* from UC Office of Grants & Contracts report.																			
17																					
18	LT 4/7/03																				

	V	W
1		TOTALS
2	3rd & 4th Qtr.	
3		
4	0	880,276
5		
6	0	35,835
7		
8	0	70,329
9		
10	0	372,725
11		
12	0	52,565
13		
14	\$0	\$1,411,730
15		
16		
17		
18		

Benzene Health Research Consortium
Irons Field Expenses 4Q03 Financial Report

	A	B	C	D	E	F
1	IRONS Field Expenses	2001	2002			2003
2	Cost Centers	4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.
3	Payments					
4	Disbursed		\$145,763	\$393,723	\$0	\$0
5	Airfare & related expenses					
6	Budgeted		\$1,280	\$103,624	\$55,343	\$27,672
7	Actual expense		\$1,606	\$75,179	\$27,359	\$25,079
8	CurrentVariance		(\$326)	\$28,445	\$27,984	\$2,593
9	Cumm Variance		(\$326)	\$28,119	\$56,103	\$58,696
10	Apartment / hotel & related expenses					
11	Budgeted		\$1,280	\$103,624	\$55,343	\$27,672
12	Actual expense		\$1,024	\$89,717	\$45,291	\$21,200
13	CurrentVariance		\$256	\$13,907	\$10,052	\$6,472
14	Cumm Variance		\$256	\$14,163	\$24,216	\$30,687
15	Other expenses e.g. taxi, limo, misc.					
16	Budgeted		\$640	\$51,812	\$27,672	\$13,836
17	Actual expense		\$528	\$30,653	\$16,926	\$8,103
18	CurrentVariance		\$112	\$21,159	\$10,746	\$47,240
19	Cumm Variance		\$112	\$21,272	\$32,017	\$79,257
20	TOTALS	2001	2002			2003
21	Budgeted		\$3,200	\$259,080	\$138,359	\$69,179
22	Actual expense		\$3,157	\$195,549	\$89,577	\$54,362
23	CurrentVariance		\$43	\$63,511	\$48,782	\$14,797
24	Cumm Variance		\$43	\$63,554	\$112,336	\$127,133
25	CUMULATIVE TOTALS	2001	2002			2003
26	Budgeted		\$3,200	\$262,280	\$400,619	\$469,798
27	Expense		\$3,157	\$198,708	\$288,283	\$342,665
28	Variance		\$43	\$63,554	\$112,336	\$127,133
29						
30	Blue: future cumulative variance has no meaning until Expense entered.	"Actual expense" is from quarterly expense reports, and does not reflect contract prepayments				4Q03 ADJUSTMENT - 2001/2002 expense underrecorded; +\$114,289 adjustment
31						
32		Amt paid to Irons to date:		\$539,486		
33		Amt Irons has spent:		\$512,270		
34	LT 4/14/04	Amt. In Irons bank acct:		\$27,216		
35						
36						
37						
38						
39						
40						
41						0

Benzene Health Research Consortium
Irons Field Expenses 4Q03 Financial Report

	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W
1	2004				2005				2006				2007				TOTALS
2	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	
3																	
4	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	
5																	
6	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$565,319
7	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$204,073
8	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$22,200	\$272,446
9	\$28,246	\$50,446	\$72,646	\$94,846	\$117,046	\$139,246	\$161,446	\$183,646	\$205,846	\$228,046	\$250,246	\$272,446	\$294,646	\$316,846	\$339,046	\$361,246	\$361,246
10																	
11	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$565,404
12	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$238,363
13	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$22,205	\$238,221
14	(\$6,034)	\$16,171	\$38,376	\$60,581	\$82,786	\$104,991	\$127,196	\$149,401	\$171,606	\$193,811	\$216,016	\$238,221	\$260,426	\$282,631	\$304,836	\$327,041	\$327,041
15																	
16	\$11,103	\$11,103	\$11,103	\$11,103	\$11,103	\$11,103	\$11,103	\$11,103	\$11,103	\$11,103	\$11,102	\$11,102	\$11,102	\$11,102	\$11,102	\$11,102	\$282,705
17	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$69,835
18	\$11,103	\$11,103	\$11,103	\$11,103	\$11,103	\$11,103	\$11,103	\$11,103	\$11,103	\$11,103	\$11,102	\$11,102	\$11,102	\$11,102	\$11,102	\$11,102	\$209,969
19	\$87,838	\$98,941	\$110,044	\$121,147	\$132,250	\$143,353	\$154,456	\$165,558	\$176,662	\$187,765	\$198,867	\$209,969	\$221,071	\$232,173	\$243,275	\$254,377	\$212,870
20	2004				2005				2006				2007				
21	\$55,508	\$55,508	\$55,508	\$55,508	\$55,508	\$55,508	\$55,508	\$55,508	\$55,508	\$55,508	\$55,507	\$55,507	\$55,507	\$55,507	\$55,507	\$55,507	\$1,413,428
22	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$512,270
23	\$55,508	\$55,508	\$55,508	\$55,508	\$55,508	\$55,508	\$55,508	\$55,508	\$55,508	\$55,508	\$55,507	\$55,507	\$55,507	\$55,507	\$55,507	\$55,507	\$679,129
24	\$68,543	\$124,051	\$179,559	\$235,067	\$290,575	\$346,083	\$401,591	\$457,099	\$512,607	\$568,115	\$623,622	\$679,129	\$734,636	\$790,143	\$845,650	\$901,157	\$901,157
25																	
26	\$580,814	\$636,322	\$691,830	\$747,338	\$802,846	\$858,354	\$913,862	\$969,370	\$1,024,878	\$1,080,386	\$1,135,893	\$1,191,400	\$1,246,907	\$1,302,414	\$1,357,921	\$1,413,428	\$1,413,428
27	\$512,270	\$512,270	\$512,270	\$512,270	\$512,270	\$512,270	\$512,270	\$512,270	\$512,270	\$512,270	\$512,270	\$512,270	\$512,270	\$512,270	\$512,270	\$512,270	\$512,270
28	\$68,543	\$124,051	\$179,559	\$235,067	\$290,575	\$346,083	\$401,591	\$457,099	\$512,607	\$568,115	\$623,622	\$679,129	\$734,636	\$790,143	\$845,650	\$901,157	\$901,157
29																	
30																	
31																	
32																	
33																	
34																	
35																	
36																	
37																	
38																	
39																	
40																	
41																	

Benzene Health Research Consortium
AHS 4Q03 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R
1	AHS (Otto Wong)	2001	2002	2003		2004				2005				2006				
2	Cost Centers	4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.
3	Labor																	
4	Budgeted	\$84,025	\$290,013	\$157,756	\$78,878	\$78,878	\$72,090	\$72,090	\$72,090	\$72,090	\$84,217	\$84,217	\$84,217	\$84,217	\$76,746	\$76,746	\$76,746	\$76,746
5	Actual expense	\$134,134	\$384,505	\$124,124	\$137,280	\$126,324	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
6	Current Variance	(\$50,109)	(\$104,492)	\$33,632	(\$58,402)	(\$47,446)	\$72,090	\$72,090	\$72,090	\$72,090	\$84,217	\$84,217	\$84,217	\$84,217	\$76,746	\$76,746	\$76,746	\$76,746
7	Cumm Variance	(\$50,109)	(\$154,601)	(\$120,970)	(\$179,372)	(\$226,818)	(\$154,728)	(\$82,638)	(\$10,547)	\$61,543	\$145,760	\$228,977	\$314,193	\$398,410	\$475,156	\$551,903	\$628,649	\$705,395
8	Travel & expenses																	
9	Budgeted	\$0	\$140,000	\$57,000	\$28,500	\$28,500	\$25,500	\$25,500	\$25,500	\$25,500	\$25,500	\$25,500	\$25,500	\$25,500	\$35,000	\$35,000	\$35,000	\$35,000
10	Actual expense	\$2,118	\$39,458	\$16,541	\$12,109	\$16,413	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
11	Current Variance	(\$2,118)	\$100,542	\$40,459	\$16,391	\$12,087	\$25,500	\$25,500	\$25,500	\$25,500	\$25,500	\$25,500	\$25,500	\$25,500	\$35,000	\$35,000	\$35,000	\$35,000
12	Cumm Variance	(\$2,118)	\$98,424	\$138,883	\$155,274	\$167,361	\$192,861	\$218,361	\$243,861	\$269,361	\$284,861	\$320,361	\$345,861	\$371,361	\$406,361	\$441,361	\$476,361	\$511,361
13	Other direct expenses																	
14	Budgeted	\$0	\$5,500	\$1,500	\$750	\$750	\$750	\$750	\$750	\$750	\$750	\$750	\$750	\$750	\$750	\$750	\$750	\$750
15	Actual expense	\$77	\$1,443	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
16	Current Variance	(\$77)	\$4,057	\$1,500	\$750	\$750	\$750	\$750	\$750	\$750	\$750	\$750	\$750	\$750	\$750	\$750	\$750	\$750
17	Cumm Variance	(\$77)	\$3,980	\$5,480	\$6,230	\$6,980	\$7,730	\$8,480	\$9,230	\$9,980	\$10,730	\$11,480	\$12,230	\$12,980	\$13,730	\$14,480	\$15,230	\$15,980
18	TOTALS	2001	2002	2003		2004				2005				2006				
19	Budgeted	\$84,025	\$435,513	\$216,256	\$108,128	\$108,128	\$98,340	\$98,340	\$98,340	\$98,340	\$110,467	\$110,467	\$110,467	\$110,467	\$112,496	\$112,496	\$112,496	\$112,496
20	Actual expense	\$136,329	\$435,406	\$140,665	\$149,389	\$142,737	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
21	Current Variance	(\$52,304)	\$107	\$75,591	(\$41,261)	(\$34,609)	\$98,340	\$98,340	\$98,340	\$98,340	\$110,467	\$110,467	\$110,467	\$110,467	\$112,496	\$112,496	\$112,496	\$112,496
22	Cumm Variance	(\$52,304)	(\$52,197)	\$23,394	(\$17,868)	(\$52,477)	\$45,863	\$144,204	\$242,544	\$340,884	\$451,351	\$561,818	\$672,284	\$782,751	\$895,247	\$1,007,744	\$1,120,240	\$1,232,736
23	CUMULATIVE TOTALS	2001	2002	2003		2004				2005				2006				
24	Budgeted	\$84,025	\$519,538	\$735,794	\$843,921	\$952,049	\$1,050,389	\$1,148,730	\$1,247,070	\$1,345,410	\$1,455,877	\$1,566,344	\$1,676,810	\$1,787,277	\$1,899,773	\$2,012,270	\$2,124,766	\$2,237,262
25	Expense	\$136,329	\$571,735	\$712,400	\$861,789	\$1,004,526	\$1,004,526	\$1,004,526	\$1,004,526	\$1,004,526	\$1,004,526	\$1,004,526	\$1,004,526	\$1,004,526	\$1,004,526	\$1,004,526	\$1,004,526	\$1,004,526
26	Variance	(\$52,304)	(\$52,197)	\$23,394	(\$17,868)	(\$52,477)	\$45,863	\$144,204	\$242,544	\$340,884	\$451,351	\$561,818	\$672,284	\$782,751	\$895,247	\$1,007,744	\$1,120,240	\$1,232,736
27	Blue: future cumulative variance has no meaning until Expense entered.																	

Benzene Health Research Consortium
AHS 4Q03 Financial Report

	S	T	U	V	W
1	2007				TOTALS
2	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	
3					
4	\$10,033	\$0	\$0	\$0	\$1,631,795
5	\$0	\$0	\$0	\$0	\$916,367
6	\$10,033	\$0	\$0	\$0	\$0
7	\$715,428	\$715,428	\$715,428	\$715,428	\$715,428
8					
9	\$32,000	\$0	\$0	\$0	\$630,000
10	\$0	\$0	\$0	\$0	\$86,639
11	\$32,000	\$0	\$0	\$0	\$0
12	\$543,361	\$543,361	\$543,361	\$543,361	\$543,361
13					
14	\$3,800	\$0	\$0	\$0	\$21,300
15	\$0	\$0	\$0	\$0	\$1,520
16	\$3,800	\$0	\$0	\$0	\$0
17	\$19,780	\$19,780	\$19,780	\$19,780	\$19,780
18	2007				
19	\$45,833	\$0	\$0	\$0	\$2,283,095
20	\$0	\$0	\$0	\$0	\$1,004,526
21	\$45,833	\$0	\$0	\$0	\$0
22	\$1,278,569	\$1,278,569	\$1,278,569	\$1,278,569	\$1,278,569
23	2007				
24	\$2,283,095	\$2,283,095	\$2,283,095	\$2,283,095	\$2,283,095
25	\$1,004,526	\$1,004,526	\$1,004,526	\$1,004,526	\$1,004,526
26	\$1,278,569	\$1,278,569	\$1,278,569	\$1,278,569	\$1,278,569
27					

Benzene Health Research Consortium
Fudan 4Q03 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S
1	FUDAN	2001	2002	2003		2004		2005		2006		2007		2008		2009		2010	
2	Cost Centers			1Q/2Q03	3Q03	4Q03	1Q04	2Q04	3Q04	4Q04	1Q05	2Q05	3Q05	4Q05	1Q06	2Q06	3Q06	4Q06	1Q07
3	Labor (salary + benefits)																		
4	Budgeted	\$9,620	\$8,775	\$4,388	\$2,194	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548
5	Actual expense	\$0	\$8,774	\$6,482	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
6	Current Variance	\$9,620	\$1	(\$2,105)	\$2,194	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548	\$1,548
7	Cumm Variance	\$9,620	\$9,621	\$7,516	\$9,709	\$11,257	\$12,805	\$14,353	\$15,901	\$17,449	\$18,997	\$20,545	\$22,093	\$23,641	\$25,189	\$26,737	\$28,285	\$29,833	\$31,381
8	Expenses																		
9	Budgeted	\$17,600	\$28,400	\$14,200	\$7,100	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645
10	Actual expense	\$0	\$4,870	\$0	\$8,851	\$1,168	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
11	Current Variance	\$17,600	\$23,530	\$14,200	(\$1,751)	\$3,477	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645	\$4,645
12	Cumm Variance	\$17,600	\$41,130	\$55,330	\$53,579	\$57,056	\$61,701	\$66,346	\$70,991	\$75,636	\$80,281	\$84,926	\$89,571	\$94,216	\$98,861	\$103,506	\$108,151	\$112,796	\$117,441
13	Overhead (15%)																		
14	Budgeted	\$4,083	\$5,576	\$2,788	\$1,394	\$1,095	\$1,095	\$1,095	\$1,095	\$1,094	\$1,094	\$1,094	\$1,094	\$1,094	\$1,094	\$1,094	\$1,094	\$1,094	\$1,094
15	Actual expense	\$0	\$1,825	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
16	Current Variance	\$4,083	\$3,751	\$2,788	\$1,394	\$1,095	\$1,095	\$1,095	\$1,095	\$1,094	\$1,094	\$1,094	\$1,094	\$1,094	\$1,094	\$1,094	\$1,094	\$1,094	\$1,094
17	Cumm Variance	\$4,083	\$7,834	\$10,622	\$12,016	\$13,111	\$14,206	\$15,301	\$16,396	\$17,490	\$18,584	\$19,678	\$20,772	\$21,866	\$22,960	\$24,054	\$25,148	\$26,242	\$27,336
18	TOTALS	2001	2002	2003		2004		2005		2006		2007		2008		2009		2010	
19	Budgeted	\$31,303	\$42,761	\$21,376	\$10,688	\$7,288	\$7,288	\$7,288	\$7,288	\$7,287	\$7,287	\$7,287	\$7,287	\$7,287	\$7,287	\$7,287	\$7,287	\$7,287	\$7,287
20	Actual expense	\$0	\$15,470	\$6,482	\$8,851	\$1,168	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
21	Current Variance	\$31,303	\$27,281	\$14,883	\$1,837	\$6,120	\$7,288	\$7,288	\$7,288	\$7,287	\$7,287	\$7,287	\$7,287	\$7,287	\$7,287	\$7,287	\$7,287	\$7,287	\$7,287
22	Cumm Variance	\$31,303	\$58,584	\$73,467	\$75,305	\$81,425	\$88,713	\$96,001	\$103,289	\$110,576	\$117,863	\$125,150	\$132,437	\$139,724	\$147,011	\$154,298	\$161,585	\$168,872	\$176,159
23	CUMULATIVE TOTALS	2001	2002	2003		2004		2005		2006		2007		2008		2009		2010	
24	Budgeted	\$31,303	\$74,054	\$95,430	\$106,117	\$113,405	\$120,693	\$127,981	\$135,269	\$142,556	\$149,843	\$157,130	\$164,417	\$171,704	\$178,991	\$186,278	\$193,565	\$200,852	\$208,139
25	Expense	\$0	\$15,470	\$21,962	\$30,813	\$31,981	\$31,981	\$31,981	\$31,981	\$31,981	\$31,981	\$31,981	\$31,981	\$31,981	\$31,981	\$31,981	\$31,981	\$31,981	\$31,981
26	Variance	\$31,303	\$58,584	\$73,467	\$75,305	\$81,425	\$88,713	\$96,001	\$103,289	\$110,576	\$117,863	\$125,150	\$132,437	\$139,724	\$147,011	\$154,298	\$161,585	\$168,872	\$176,159
27	Blue: future cumulative variance has no meaning until Expense entered.															Note: budget is in 2001 \$.			

Benzene Health Research Consortium
Fudan 4Q03 Financial Report

	T	U	V	W
1	2007			TOTALS
2	2Q07	3Q07	4Q07	
3				
4	\$1,548	\$1,548	\$1,548	\$51,292
5	\$0	\$0	\$0	\$15,267
6	\$1,548	\$1,548	\$1,548	\$1,548
7	\$32,929	\$34,477	\$36,025	\$36,025
8				
9	\$4,645	\$4,645	\$4,645	\$146,265
10	\$0	\$0	\$0	\$14,889
11	\$4,645	\$4,645	\$4,645	\$4,645
12	\$122,086	\$126,731	\$131,376	\$131,376
13				
14	\$1,094	\$1,094	\$1,094	\$32,443
15	\$0	\$0	\$0	\$1,825
16	\$1,094	\$1,094	\$1,094	\$1,094
17	\$28,430	\$29,524	\$30,618	\$30,618
18	2007			
19	\$7,287	\$7,287	\$7,287	\$230,000
20	\$0	\$0	\$0	\$31,981
21	\$7,287	\$7,287	\$7,287	\$7,287
22	\$183,446	\$190,733	\$198,020	\$198,020
23	2007			
24	\$215,426	\$222,713	\$230,000	\$230,000
25	\$31,981	\$31,981	\$31,981	\$31,981
26	\$183,446	\$190,733	\$198,020	\$198,020
27				

	U	V	W
1	07		TOTALS
2	3rd Qtr.	4th Qtr.	
3			
4	\$321	\$321	\$22,750
5	\$0	\$0	\$4,529
6	\$321	\$321	\$321
7	\$17,900	\$18,221	\$18,221
8			
9	\$321	\$321	\$22,750
10	\$0	\$0	\$0
11	\$321	\$321	\$321
12	\$22,429	\$22,750	\$22,750
13			
14	\$321	\$321	\$22,750
15	\$0	\$0	\$3,422
16	\$321	\$321	\$321
17	\$19,007	\$19,328	\$19,328
18			
19	\$321	\$321	\$22,750
20	\$0	\$0	\$2,122
21	\$321	\$321	\$321
22	\$20,307	\$20,628	\$20,628
23			
24	\$321	\$321	\$22,750
25	\$0	\$0	\$7,334
26	\$321	\$321	\$321
27	\$15,095	\$15,416	\$15,416
28			
29	\$321	\$321	\$22,750
30	\$0	\$0	\$6,454
31	\$321	\$321	\$321
32	\$15,975	\$16,296	\$16,296
33			
34	\$321	\$321	\$22,750
35	\$0	\$0	\$4,524
36	\$321	\$321	\$321
37	\$17,905	\$18,226	\$18,226
38			
39	\$321	\$321	\$22,750
40	\$0	\$0	\$4,763
41	\$321	\$321	\$321
42	\$17,666	\$17,987	\$17,987
43			
44	\$321	\$321	\$22,750
45	\$0	\$0	\$22,890
46	\$321	\$321	\$321
47	(\$461)	(\$140)	(\$140)
48			
49	\$321	\$321	\$22,750
50	\$0	\$0	\$1,000
51	\$321	\$321	\$321
52	\$21,429	\$21,750	\$21,750
53			
54	\$321	\$321	\$22,750
55	\$0	\$0	\$1,250
56	\$321	\$321	\$321
57	\$21,179	\$21,500	\$21,500
58			
59	\$321	\$321	\$22,750
60	\$0	\$0	\$11,692
61	\$321	\$321	\$321
62	\$10,737	\$11,058	\$11,058
63			
64	\$321	\$321	\$22,750
65	\$0	\$0	\$2,670
66	\$321	\$321	\$321
67	\$19,759	\$20,080	\$20,080
68			
69	\$321	\$321	\$22,750
70	\$0	\$0	\$10,204
71	\$321	\$321	\$321
72	\$12,225	\$12,546	\$12,546
73			
74	\$321	\$321	\$22,750
75	\$0	\$0	\$0
76	\$321	\$321	\$321
77	\$22,429	\$22,750	\$22,750
78			
79	\$321	\$321	\$22,750
80	\$0	\$0	\$0
81	\$321	\$321	\$321
82	\$22,429	\$22,750	\$22,750
83	07		
84	\$5,136	\$5,136	\$364,000
85	\$0	\$0	\$82,854
86	\$5,136	\$5,136	\$5,136
87	\$276,010	\$281,146	\$281,146
88	07		
89	\$368,864	\$364,000	\$364,000
90	\$82,854	\$82,854	\$82,854
91	\$276,010	\$281,146	\$281,146
92			

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T
93	Blue: future cumulative variance has no meaning until Expense entered.																			

**Benzene Health Research Consortium
Communications 4Q03 Financial Report**

	A	B	C	D	E	F	G	H	I	J	K	L
1	COMMUNICATIONS	2001	2002	2003				2004				2004
2	Cost Centers	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.^c	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.
3	APCO											
4	Budgeted	\$57,600	\$230,400	\$120,000	\$60,000	(\$187,396)	\$14,401	\$14,400	\$14,400	\$14,400	\$14,400	\$14,400
5	Actual expense	\$0	\$232,229	\$14,483	\$7,351	\$26,541	\$0	\$0	\$0	\$0	\$0	\$0
6	CurrentVariance	\$57,600	(\$1,829)	\$105,517	\$52,649	(\$213,937)	\$14,401	\$14,400	\$14,400	\$14,400	\$14,400	\$14,400
7	Cumm Variance	\$57,600	\$55,771	\$161,288	\$213,937	(\$0)	\$14,401	\$28,801	\$43,201	\$57,601	\$72,001	\$86,401
8	Travel											
9	Budgeted	\$1,800	\$7,200	\$3,750	\$1,875	(\$5,876)	\$450	\$450	\$450	\$450	\$450	\$450
10	Actual expense	\$0	\$7,091	\$0	\$526	\$1,132	\$0	\$0	\$0	\$0	\$0	\$0
11	CurrentVariance	\$1,800	\$109	\$3,750	\$1,349	(\$7,008)	\$450	\$450	\$450	\$450	\$450	\$450
12	Cumm Variance	\$1,800	\$1,909	\$5,659	\$7,008	\$0	\$450	\$900	\$1,350	\$1,800	\$2,250	\$2,700
13	Other¹											
14	Budgeted	\$600	\$2,400	\$1,250	\$625	(\$3,364)	\$150	\$150	\$150	\$150	\$150	\$150
15	Actual expense	\$0	\$1,417	\$80	\$0	\$15	\$0	\$0	\$0	\$0	\$0	\$0
16	CurrentVariance	\$600	\$983	\$1,170	\$625	(\$3,379)	\$150	\$150	\$150	\$150	\$150	\$150
17	Cumm Variance	\$600	\$1,583	\$2,753	\$3,378	(\$2)	\$148	\$298	\$448	\$598	\$748	\$898
18												
19	Budgeted	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
20	Actual expense	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
21	CurrentVariance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
22	Cumm Variance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
23												
24	Budgeted	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
25	Actual expense	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
26	CurrentVariance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
27	Cumm Variance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
28												
29	Budgeted	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
30	Actual expense	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
31	CurrentVariance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
32	Cumm Variance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
33												
34	Budgeted	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
35	Actual expense	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
36	CurrentVariance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
37	Cumm Variance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
38	TOTALS	2001	2002	2003				2004				2004
39	Budgeted	\$60,000	\$240,000	\$125,000	\$62,500	(\$196,636)	\$15,001	\$15,000	\$15,000	\$15,000	\$15,000	\$15,000
40	Actual expense	\$0	\$240,738	\$14,564	\$7,877	\$27,688	\$0	\$0	\$0	\$0	\$0	\$0
41	CurrentVariance	\$60,000	(\$738)	\$110,436	\$54,623	(\$224,324)	\$15,001	\$15,000	\$15,000	\$15,000	\$15,000	\$15,000
42	Cumm Variance	\$60,000	\$59,262	\$169,699	\$224,322	(\$2)	\$14,999	\$29,999	\$44,999	\$59,999	\$74,999	\$89,999
43	CUMULATIVE TOTALS	2001	2002	2003				2004				2004
44	Budgeted	\$60,000	\$300,000	\$425,000	\$487,500	\$290,864	\$305,865	\$320,865	\$335,865	\$350,865	\$365,865	\$380,865
45	Expense	\$0	\$240,738	\$255,301	\$263,178	\$290,866	\$290,866	\$290,866	\$290,866	\$290,866	\$290,866	\$290,866
46	Variance	\$60,000	\$59,262	\$169,699	\$224,322	(\$2)	\$14,999	\$29,999	\$44,999	\$59,999	\$74,999	\$89,999
47	- Telecommunications, Consulting Services, Duplicating/Copies Internal, Postage, Couriers, Telephone, Meals, Lexis Nexis Searches											
48	Blue: future cumulative variance has no meaning until Expense entered.											
49	c - Budget adjustment reflects budget reduction from \$1MM to \$550k											

**Benzene Health Research Consortium
Communications 4Q03 Financial Report**

	M	N	O	P	Q	R	S	T	U	V	W
1	2006				2007				TOTALS		
2	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	
3											
4	\$14,400	\$14,400	\$14,400	\$14,400	\$14,400	\$14,400	\$18,865	\$18,865	\$18,866	\$18,866	\$528,867
5	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$280,604
6	\$14,400	\$14,400	\$14,400	\$14,400	\$14,400	\$14,400	\$18,865	\$18,865	\$18,866	\$18,866	\$248,263
7	\$100,801	\$115,201	\$129,601	\$144,001	\$158,401	\$172,801	\$191,666	\$210,531	\$229,397	\$248,263	\$248,263
8											
9	\$450	\$450	\$450	\$450	\$450	\$450	\$689	\$689	\$689	\$689	\$16,904
10	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$8,749
11	\$450	\$450	\$450	\$450	\$450	\$450	\$689	\$689	\$689	\$689	\$8,155
12	\$3,150	\$3,600	\$4,050	\$4,500	\$4,950	\$5,400	\$6,089	\$6,778	\$7,466	\$8,155	\$8,155
13											
14	\$150	\$150	\$150	\$150	\$150	\$150	\$230	\$230	\$230	\$230	\$4,229
15	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$1,513
16	\$150	\$150	\$150	\$150	\$150	\$150	\$230	\$230	\$230	\$230	\$2,717
17	\$1,048	\$1,198	\$1,348	\$1,498	\$1,648	\$1,798	\$2,028	\$2,257	\$2,487	\$2,717	\$2,717
18											
19	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
20	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
21	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
22	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
23											
24	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
25	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
26	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
27	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
28											
29	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
30	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
31	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
32	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
33											
34	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
35	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
36	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
37	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
38	2006				2007						
39	\$15,000	\$15,000	\$15,000	\$15,000	\$15,000	\$15,000	\$19,783	\$19,783	\$19,784	\$19,784	\$550,000
40	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$290,866
41	\$15,000	\$15,000	\$15,000	\$15,000	\$15,000	\$15,000	\$19,783	\$19,783	\$19,784	\$19,784	\$179,999
42	\$104,999	\$119,999	\$134,999	\$149,999	\$164,999	\$179,999	\$199,782	\$219,566	\$239,350	\$259,134	\$259,134
43	2006				2007						
44	\$395,865	\$410,865	\$425,865	\$440,865	\$455,865	\$470,865	\$490,648	\$510,431	\$530,216	\$550,000	\$550,000
45	\$290,866	\$290,866	\$290,866	\$290,866	\$290,866	\$290,866	\$290,866	\$290,866	\$290,866	\$290,866	\$290,866
46	\$104,999	\$119,999	\$134,999	\$149,999	\$164,999	\$179,999	\$199,782	\$219,566	\$239,350	\$259,134	\$259,134
47											
48											
49											

Benzene Health Research Consortium
Legal 4Q03 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V
1	LEGAL	2001	2002	2003		2004				2005				2006				2007				
2	Cost Centers	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.*	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.
3	Step toe & Johnson																					
4	Budgeted	\$30,000	\$120,000	\$62,500	\$31,250	(\$210,542)	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175
5	Actual expense	\$0	\$13,565	\$1,728	\$0	\$17,915	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
6	Current/Variance	\$30,000	\$106,435	\$60,772	\$31,250	(\$228,457)	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175	\$4,175
7	Cumm Variance	\$30,000	\$136,435	\$197,207	\$228,457	\$0	\$4,175	\$8,349	\$12,524	\$16,698	\$20,873	\$25,047	\$29,222	\$33,396	\$37,571	\$41,745	\$45,920	\$50,094	\$54,269	\$58,443	\$62,618	\$66,792
8	CUMULATIVE TOTALS	2001	2002	2003		2004				2005				2006				2007				
9	Budgeted	\$30,000	\$150,000	\$212,500	\$243,750	\$33,208	\$37,383	\$41,557	\$45,732	\$49,906	\$54,081	\$58,255	\$62,430	\$66,604	\$70,779	\$74,953	\$79,128	\$83,302	\$87,477	\$91,651	\$95,826	\$100,000
10	Expense	\$0	\$13,565	\$15,293	\$15,293	\$33,208	\$33,208	\$33,208	\$33,208	\$33,208	\$33,208	\$33,208	\$33,208	\$33,208	\$33,208	\$33,208	\$33,208	\$33,208	\$33,208	\$33,208	\$33,208	\$33,208
11	Variance	\$30,000	\$136,435	\$197,207	\$228,457	\$0	\$4,175	\$8,349	\$12,524	\$16,698	\$20,873	\$25,047	\$29,222	\$33,396	\$37,571	\$41,745	\$45,920	\$50,094	\$54,269	\$58,443	\$62,618	\$66,792
12	Blue: future cumulative variance has no meaning until Expense entered.																					
13																						
14	* budget adjustment to lower program budget from \$500K to \$100K, as approved by OC on 11/11/03																					
15																						
16	LT 4/7/04																					

Benzene Health Research Consortium
Legal 4Q03 Financial Report

	W
1	TOTALS
2	
3	
4	\$100,000
5	\$33,208
6	\$66,792
7	\$66,792
8	
9	\$100,000
10	\$33,208
11	\$66,792
12	
13	
14	
15	
16	

**Benzene Health Research Consortium
QA-QC 4Q03 Financial Report**

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V
1	QA-QC	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
2	Cost Centers	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.
3	Contractor																					
4	Budgeted	\$13,500	\$54,000	\$28,126	\$14,063	(\$109,689)	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250
5	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
6	CurrentVariance	\$13,500	\$54,000	\$28,126	\$14,063	(\$109,689)	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250
7	Cumm Variance	\$13,500	\$67,500	\$95,626	\$109,689	\$0	\$6,250	\$12,500	\$18,750	\$25,000	\$31,250	\$37,500	\$43,750	\$50,000	\$56,250	\$62,500	\$68,750	\$75,000	\$81,250	\$87,500	\$93,750	\$100,000
8	Travel																					
9	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
10	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
11	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
12	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
13																						
14	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
15	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
16	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
17	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
18																						
19	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
20	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
21	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
22	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
23																						
24	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
25	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
26	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
27	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
28																						
29	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
30	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
31	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
32	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
33																						
34	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
35	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
36	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
37	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
38	TOTALS	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
39	Budgeted	\$13,500	\$54,000	\$28,126	\$14,063	(\$109,689)	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250
40	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
41	CurrentVariance	\$13,500	\$54,000	\$28,126	\$14,063	(\$109,689)	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250	\$6,250
42	Cumm Variance	\$13,500	\$67,500	\$95,626	\$109,689	\$0	\$6,250	\$12,500	\$18,750	\$25,000	\$31,250	\$37,500	\$43,750	\$50,000	\$56,250	\$62,500	\$68,750	\$75,000	\$81,250	\$87,500	\$93,750	\$100,000
43	CUMULATIVE TOTALS	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
44	Budgeted	\$13,500	\$67,500	\$95,626	\$109,689	\$0	\$6,250	\$12,500	\$18,750	\$25,000	\$31,250	\$37,500	\$43,750	\$50,000	\$56,250	\$62,500	\$68,750	\$75,000	\$81,250	\$87,500	\$93,750	\$100,000
45	Expense	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
46	Variance	\$13,500	\$67,500	\$95,626	\$109,689	\$0	\$6,250	\$12,500	\$18,750	\$25,000	\$31,250	\$37,500	\$43,750	\$50,000	\$56,250	\$62,500	\$68,750	\$75,000	\$81,250	\$87,500	\$93,750	\$100,000
47	Blue: future cumulative																					
48	variance has no meaning																					
49	until Expense entered.																					
50	* budget adjustment to lower program																					
51	budget from \$225K to \$100K, as																					
	approved by OC on 11/11/03																					
	LT 4/7/04																					

Benzene Health Research Consortium
QA-QC 4Q03 Financial Report

	W
1	TOTALS
2	
3	
4	\$100,000
5	\$0
6	\$100,000
7	\$100,000
8	
9	\$0
10	\$0
11	\$0
12	\$0
13	
14	\$0
15	\$0
16	\$0
17	\$0
18	
19	\$0
20	\$0
21	\$0
22	\$0
23	
24	\$0
25	\$0
26	\$0
27	\$0
28	
29	\$0
30	\$0
31	\$0
32	\$0
33	
34	\$0
35	\$0
36	\$0
37	\$0
38	
39	\$100,000
40	\$0
41	\$100,000
42	\$100,000
43	
44	\$100,000
45	\$0
46	\$100,000
47	
48	
49	
50	
51	

Benzene Health Research Consortium
API Administration 4Q03 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P
1	API	2000	2001	2002	2003			2004				2005				
2	Cost Centers	1st - 4th Qtr.	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.
3	Salaries															
4	Budgeted	\$0	\$0	\$85,700	\$44,500	\$22,250	\$22,250	\$27,250	\$27,250	\$27,250	\$27,250	\$15,000	\$15,000	\$15,000	\$15,000	\$15,000
5	Actual expense	\$9,039	\$18,749	\$89,669	\$57,297	\$32,217	\$32,800	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
6	CurrentVariance	(\$9,039)	\$6,552	(\$3,969)	(\$12,797)	(\$9,967)	(\$10,550)	\$27,250	\$27,250	\$27,250	\$27,250	\$15,000	\$15,000	\$15,000	\$15,000	\$15,000
7	Cumm Variance	(\$9,039)	(\$2,487)	(\$6,456)	(\$19,253)	(\$29,220)	(\$39,770)	(\$12,520)	\$14,730	\$41,980	\$69,230	\$84,230	\$99,230	\$114,230	\$129,230	\$144,230
8	Employee Benefits															
9	Budgeted	\$0	\$0	\$10,900	\$ 5,500	\$ 2,750	\$ 2,750	\$3,250	\$3,250	\$3,250	\$3,250	\$1,500	\$1,500	\$1,500	\$1,500	\$1,500
10	Actual expense	\$774	\$2,329	\$11,209	\$7,162	\$4,027	\$4,100	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
11	CurrentVariance	(\$774)	(\$2,329)	(\$309)	(\$1,662)	(\$1,277)	(\$1,350)	\$3,250	\$3,250	\$3,250	\$3,250	\$1,500	\$1,500	\$1,500	\$1,500	\$1,500
12	Cumm Variance	(\$774)	(\$3,103)	(\$3,412)	(\$5,074)	(\$6,351)	(\$7,701)	(\$4,451)	(\$1,201)	\$2,049	\$5,299	\$6,799	\$8,299	\$9,799	\$11,299	\$12,799
13	Travel															
14	Budgeted	\$0	\$0	\$50,000	15,000	\$7,500	\$7,500	\$1,250	\$1,250	\$1,250	\$1,250	\$1,000	\$1,000	\$5,000	\$1,000	\$1,000
15	Actual expense	\$342	\$0	\$4,686	\$0	\$0	\$7,313	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
16	CurrentVariance	(\$342)	\$0	\$45,314	\$15,000	\$7,500	\$187	\$1,250	\$1,250	\$1,250	\$1,250	\$1,000	\$1,000	\$5,000	\$1,000	\$1,000
17	Cumm Variance	(\$342)	(\$342)	\$44,972	\$59,972	\$67,472	\$67,659	\$68,909	\$70,159	\$71,409	\$72,659	\$73,659	\$74,659	\$79,659	\$80,659	\$81,659
18	Other Operating Expenses (& mtgs)															
19	Budgeted	\$0	\$0	\$10,300	\$5,000	\$2,500	\$18,205	\$6,000	\$6,000	\$6,000	\$6,000	\$1,500	\$1,500	\$5,000	\$1,500	\$1,500
20	Actual expense	\$1,673	\$4,173	\$6,140	\$5,077	\$1,755	\$26,276	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
21	CurrentVariance	(\$1,673)	(\$4,173)	\$4,160	(\$77)	\$745	(\$8,071)	\$6,000	\$6,000	\$6,000	\$6,000	\$1,500	\$1,500	\$5,000	\$1,500	\$1,500
22	Cumm Variance	(\$1,673)	(\$5,846)	(\$1,687)	(\$1,764)	(\$1,019)	(\$9,090)	(\$3,090)	\$2,910	\$8,910	\$14,910	\$16,410	\$17,910	\$22,910	\$24,410	\$25,910
23	API Recovered Overhead															
24	Budgeted	\$0	\$0	\$18,500	\$ 12,500	\$ 6,250	\$ 6,250	\$7,500	\$7,500	\$7,500	\$7,500	\$4,000	\$4,000	\$4,000	\$4,000	\$4,000
25	Actual expense	\$5,752	\$4,687	\$25,110	\$16,043	\$9,021	\$9,185	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
26	CurrentVariance	(\$5,752)	(\$4,687)	(\$6,610)	(\$3,543)	(\$2,771)	(\$2,935)	\$7,500	\$7,500	\$7,500	\$7,500	\$4,000	\$4,000	\$4,000	\$4,000	\$4,000
27	Cumm Variance	(\$5,752)	(\$10,439)	(\$17,049)	(\$20,592)	(\$23,363)	(\$26,298)	(\$18,798)	(\$11,298)	(\$3,798)	\$3,702	\$7,702	\$11,702	\$15,702	\$19,702	\$23,702
28	API Allocated Costs															
29	Budgeted	\$0	\$0	\$60,600	\$30,500	\$15,250	\$15,250	\$28,000	\$28,000	\$28,000	\$28,000	\$10,000	\$10,000	\$10,000	\$10,000	\$10,000
30	Actual expense	\$0	\$13,886	\$58,794	\$34,213	\$19,478	\$17,231	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
31	CurrentVariance	\$0	(\$13,886)	\$1,806	(\$3,713)	(\$4,228)	(\$1,981)	\$28,000	\$28,000	\$28,000	\$28,000	\$10,000	\$10,000	\$10,000	\$10,000	\$10,000
32	Cumm Variance	\$0	(\$13,886)	(\$12,080)	(\$15,793)	(\$20,021)	(\$22,002)	\$5,998	\$33,998	\$61,998	\$89,998	\$99,998	\$109,998	\$119,998	\$129,998	\$139,998
33	Supported Expense															
34	Budgeted	\$0	\$0	\$0	\$ 11,500	\$ 5,750	\$5,750	\$4,500	\$4,500	\$4,500	\$4,500	\$1,250	\$1,250	\$1,250	\$1,250	\$1,250
35	Actual expense	\$7,020	\$1,712	\$0	\$17,000	\$8,499	(\$8,250)	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
36	CurrentVariance	(\$7,020)	(\$1,712)	\$0	(\$5,500)	(\$2,749)	\$14,000	\$4,500	\$4,500	\$4,500	\$4,500	\$1,250	\$1,250	\$1,250	\$1,250	\$1,250
37	Cumm Variance	(\$7,020)	(\$8,732)	(\$8,732)	(\$14,232)	(\$16,981)	(\$2,981)	\$1,519	\$6,019	\$10,519	\$15,019	\$16,269	\$17,519	\$18,769	\$20,019	\$21,269
38	TOTALS	2000	2001	2002	2003			2004				2005				
39	Budgeted	\$0	\$0	\$236,000	\$124,500	\$62,250	\$77,955	\$77,750	\$77,750	\$77,750	\$77,750	\$34,250	\$34,250	\$41,750	\$34,250	\$34,250
40	Actual expense	\$24,600	\$45,536	\$195,608	\$136,792	\$74,997	\$88,655	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
41	CurrentVariance	(\$24,600)	(\$45,536)	\$40,392	(\$12,292)	(\$12,747)	(\$10,700)	\$77,750	\$77,750	\$77,750	\$77,750	\$34,250	\$34,250	\$41,750	\$34,250	\$34,250
42	Cumm Variance	(\$24,600)	(\$70,136)	(\$29,745)	(\$42,037)	(\$54,784)	(\$65,484)	\$12,266	\$90,016	\$167,766	\$245,516	\$279,766	\$314,016	\$355,766	\$390,016	\$424,266
43	CUMULATIVE TOTALS	2000	2001	2002	2003			2004				2005				
44	Budgeted	\$0	\$0	\$236,000	\$360,500	\$422,750	\$500,705	\$578,455	\$656,205	\$733,955	\$811,705	\$845,955	\$880,205	\$921,955	\$956,205	\$990,455
45	Expense	\$24,600	\$70,136	\$265,745	\$402,537	\$477,534	\$566,189	\$566,189	\$566,189	\$566,189	\$566,189	\$566,189	\$566,189	\$566,189	\$566,189	\$566,189
46	Variance	(\$24,600)	(\$70,136)	(\$29,745)	(\$42,037)	(\$54,784)	(\$65,484)	\$12,266	\$90,016	\$167,766	\$245,516	\$279,766	\$314,016	\$355,766	\$390,016	\$424,266
47																
48	LT 4/14/04															
49																
50	Assumptions:															
51	Year 5, 6, 7 Less than 1 FTE allocated, based allocated cost on 1/2 FTE															
52	T&E and Other \$15K for Annual Meeting (3rd Quarter)															
53	Supported Expense, drop off left some funds for consultant															

Benzene Health Research Consortium
API Administration 4Q03 Financial Report

	Q	R	S	T	U	V	W	X
1	2006			2007				TOTALS
2	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	
3								
4	\$15,000	\$15,000	\$15,000	\$15,000	\$15,000	\$15,000	\$15,000	\$403,700
5	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$230,732
6	\$15,000	\$15,000	\$15,000	\$15,000	\$15,000	\$15,000	\$15,000	\$198,269
7	\$159,230	\$174,230	\$189,230	\$204,230	\$219,230	\$234,230	\$249,230	\$172,968
8								
9	\$1,500	\$1,500	\$1,500	\$1,500	\$1,500	\$1,500	\$1,500	\$52,900
10	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$28,827
11	\$1,500	\$1,500	\$1,500	\$1,500	\$1,500	\$1,500	\$1,500	\$24,073
12	\$14,299	\$15,799	\$17,299	\$18,799	\$20,299	\$21,799	\$23,299	\$24,073
13								
14	\$1,000	\$5,000	\$1,000	\$1,000	\$1,000	\$5,000	\$1,000	\$109,000
15	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$11,999
16	\$1,000	\$5,000	\$1,000	\$1,000	\$1,000	\$5,000	\$1,000	\$97,001
17	\$82,659	\$87,659	\$88,659	\$89,659	\$90,659	\$95,659	\$96,659	\$97,001
18								
19	\$1,500	\$5,000	\$1,500	\$1,500	\$1,500	\$5,000	\$1,500	\$88,505
20	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$43,422
21	\$1,500	\$5,000	\$1,500	\$1,500	\$1,500	\$5,000	\$1,500	\$45,083
22	\$27,410	\$32,410	\$33,910	\$35,410	\$36,910	\$41,910	\$43,410	\$45,083
23								
24	\$4,000	\$4,000	\$4,000	\$4,000	\$4,000	\$4,000	\$4,000	\$121,500
25	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$64,046
26	\$4,000	\$4,000	\$4,000	\$4,000	\$4,000	\$4,000	\$4,000	\$57,454
27	\$27,702	\$31,702	\$35,702	\$39,702	\$43,702	\$47,702	\$51,702	\$57,454
28								
29	\$10,000	\$10,000	\$10,000	\$10,000	\$10,000	\$10,000	\$10,000	\$353,600
30	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$143,602
31	\$10,000	\$10,000	\$10,000	\$10,000	\$10,000	\$10,000	\$10,000	\$209,998
32	\$149,998	\$159,998	\$169,998	\$179,998	\$189,998	\$199,998	\$209,998	\$209,998
33								
34	\$1,250	\$1,250	\$1,250	\$1,250	\$1,250	\$1,250	\$1,250	\$56,000
35	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$18,961
36	\$1,250	\$1,250	\$1,250	\$1,250	\$1,250	\$1,250	\$1,250	\$37,039
37	\$22,519	\$23,769	\$25,019	\$26,269	\$27,519	\$28,769	\$30,019	\$37,039
38	2006			2007				
39	\$34,250	\$41,750	\$34,250	\$34,250	\$34,250	\$41,750	\$34,250	\$1,245,205
40	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$541,589
41	\$34,250	\$41,750	\$34,250	\$34,250	\$34,250	\$41,750	\$34,250	\$703,616
42	\$458,516	\$500,266	\$534,516	\$568,766	\$603,016	\$644,766	\$679,016	\$703,616
43	2006			2007				
44	\$1,024,705	\$1,066,455	\$1,100,705	\$1,134,955	\$1,169,205	\$1,210,955	\$1,245,205	\$1,245,205
45	\$566,189	\$566,189	\$566,189	\$566,189	\$566,189	\$566,189	\$566,189	\$566,189
46	\$458,516	\$500,266	\$534,516	\$568,766	\$603,016	\$644,766	\$679,016	\$679,016
47								
48								
49								
50								
51								
52								
53								

Benzene Health Research Consortium
Contingency Fund 4Q03 Financial Report

	A	B	C	D	E	F	G
1							
2		2000	2001	2002		2003	
3	Contingency Funds	1st - 4th Qtr.	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.
4							
5	Budgeted	\$0	\$0	\$0	\$0	\$0	\$390,272
6	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0
7	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$390,272
8	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$390,272
9	Reallocations from UCHSC						
10	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0
11	Actual expense	\$0	\$0	\$0	\$0	\$0	\$48,839
12	CurrentVariance	\$0	\$0	\$0	\$0	\$0	(\$48,839)
13	Cumm Variance	\$0	\$0	\$0	\$0	\$0	(\$48,839)
14							
15	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0
16	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0
17	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$0
18	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$0
19							
20	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0
21	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0
22	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$0
23	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$0
24							
25	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0
26	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0
27	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$0
28	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$0
29							
30	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0
31	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0
32	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$0
33	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$0
34							
35	Budgeted	\$0	\$0	\$0	\$0	\$0	\$0
36	Actual expense	\$0	\$0	\$0	\$0	\$0	\$0
37	CurrentVariance	\$0	\$0	\$0	\$0	\$0	\$0
38	Cumm Variance	\$0	\$0	\$0	\$0	\$0	\$0
39	TOTALS	2000	2001	2002		2003	
40	Budgeted	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$390,272.00
41	Actual expense	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$48,839.00
42	CurrentVariance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$341,433.00
43	Cumm Variance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$341,433.00
44	CUMULATIVE TOTALS	2000	2001	2002		2003	
45	Budgeted	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$390,272.00
46	Expense	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$48,839.00
47	Variance	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$341,433.00
48							
49							
50	LT 4/7/04						
51							4Q03 Adjustment.
52							
53							
54							

Benzene Health Research Consortium
Contingency Fund 4Q03 Financial Report

	H	I	J	K	L	M	N
1							
2	2004					2005	
3	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.
4							
5	\$0	\$0	\$0	\$0	\$0	\$0	\$0
6	\$0	\$0	\$0	\$0	\$0	\$0	\$0
7	\$0	\$0	\$0	\$0	\$0	\$0	\$0
8	\$390,272	\$390,272	\$390,272	\$390,272	\$390,272	\$390,272	\$390,272
9							
10	\$0	\$0	\$0	\$0	\$0	\$0	\$0
11	\$0	\$0	\$0	\$0	\$0	\$0	\$0
12	\$0	\$0	\$0	\$0	\$0	\$0	\$0
13	(\$48,839)	(\$48,839)	(\$48,839)	(\$48,839)	(\$48,839)	(\$48,839)	(\$48,839)
14							
15	\$0	\$0	\$0	\$0	\$0	\$0	\$0
16	\$0	\$0	\$0	\$0	\$0	\$0	\$0
17	\$0	\$0	\$0	\$0	\$0	\$0	\$0
18	\$0	\$0	\$0	\$0	\$0	\$0	\$0
19							
20	\$0	\$0	\$0	\$0	\$0	\$0	\$0
21	\$0	\$0	\$0	\$0	\$0	\$0	\$0
22	\$0	\$0	\$0	\$0	\$0	\$0	\$0
23	\$0	\$0	\$0	\$0	\$0	\$0	\$0
24							
25	\$0	\$0	\$0	\$0	\$0	\$0	\$0
26	\$0	\$0	\$0	\$0	\$0	\$0	\$0
27	\$0	\$0	\$0	\$0	\$0	\$0	\$0
28	\$0	\$0	\$0	\$0	\$0	\$0	\$0
29							
30	\$0	\$0	\$0	\$0	\$0	\$0	\$0
31	\$0	\$0	\$0	\$0	\$0	\$0	\$0
32	\$0	\$0	\$0	\$0	\$0	\$0	\$0
33	\$0	\$0	\$0	\$0	\$0	\$0	\$0
34							
35	\$0	\$0	\$0	\$0	\$0	\$0	\$0
36	\$0	\$0	\$0	\$0	\$0	\$0	\$0
37	\$0	\$0	\$0	\$0	\$0	\$0	\$0
38	\$0	\$0	\$0	\$0	\$0	\$0	\$0
39	2004					2005	
40	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
41	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
42	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
43	\$341,433.00	\$341,433.00	\$341,433.00	\$341,433.00	\$341,433.00	\$341,433.00	\$341,433.00
44	2004					2005	
45	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
46	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
47	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
48							
49							
50							
51	per Technical Committee, transfer \$48,839 from UCHSC budget detail to contingency because expenses not part of UCHSC grant budget:						
52	1. June 2001 \$25K grant to UCHSC; seed money exhausted (API & sponsor), expense not included in final grant cost estimate						
53	2. \$3600 IRB fees to U of CO (this will be a yearly fee, since IRB must review at least once per year)						
54	3. 2002 invoice (\$20,239) from EMBSI for final feasibility study work (very late billing to API)						

Benzene Health Research Consortium
Contingency Fund 4Q03 Financial Report

	O	P	Q	R	S	T	U	V	W	X
1										
2		2006					2007			
3	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	TOTALS
4										
5	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$390,272
6	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
7	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
8	\$390,272	\$390,272	\$390,272	\$390,272	\$390,272	\$390,272	\$390,272	\$390,272	\$390,272	\$390,272
9										
10	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
11	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$48,839
12	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
13	(\$48,839)	(\$48,839)	(\$48,839)	(\$48,839)	(\$48,839)	(\$48,839)	(\$48,839)	(\$48,839)	(\$48,839)	(\$48,839)
14										
15	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
16	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
17	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
18	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
19										
20	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
21	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
22	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
23	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
24										
25	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
26	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
27	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
28	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
29										
30	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
31	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
32	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
33	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
34										
35	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
36	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
37	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
38	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
39										
40	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$390,272.00
41	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$48,839.00
42	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
43	\$341,433.00	\$341,433.00	\$341,433.00	\$341,433.00	\$341,433.00	\$341,433.00	\$341,433.00	\$341,433.00	\$341,433.00	\$341,433.00
44										
45	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
46	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
47	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
48										
49										
50										
51										
52										
53										
54										

Benzene Health Research Consortium
Income 4Q03 Financial Report

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R
1		2000	2001	2002		2003			2004				2005				2006	
2		1st - 4th Qtr.	1st - 4th Qtr.	1st - 4th Qtr.	1st & 2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.
3	INCOME																	
4	Sponsor Payments	\$60,000	\$2,105,509	\$8,355,629	\$448,024	\$0	\$ 4,259,964.50	\$1,485,875									\$100,000	
5	Interest	\$246	\$7,623	\$11,817	\$0	\$3,186	\$5,276		\$5,000									
6	Other	\$0	\$0	\$0	\$0	\$0												
7	TOTALS																	
8	Reporting Period	\$60,246	\$2,113,132	\$8,367,446	\$448,024	\$3,186	\$4,265,241	\$1,485,875	\$5,000	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$100,000	\$0
9	Cumulative	\$60,246	\$2,173,378	\$10,540,824	\$10,988,848	\$10,992,034	\$15,257,275	\$16,743,149	\$16,748,149	\$16,748,149	\$16,748,149	\$16,748,149	\$16,748,149	\$16,748,149	\$16,748,149	\$16,748,149	\$16,848,149	\$16,848,149
10																		
11																		
12	projected income																	
13																		
14	LT 4/7/04																	

Benzene Health Research Consortium
Income 4Q03 Financial Report

	S	T	U	V	W	X
1						
2	4th Qtr.	1st Qtr.	2nd Qtr.	3rd Qtr.	4th Qtr.	TOTALS
3						
4						
5						
6						
7						
8	\$0	\$0	\$0	\$0	\$0	
9	\$16,848,149	\$16,848,149	\$16,848,149	\$16,848,149	\$16,848,149	
10						
11						
12						
13						
14						

**Benzene Health Research Consortium
Sponsor Invoice Detail 4Q03 Financial Report**

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q
1					2001			2002			3rd - 4th Qtr.			2003			
2	Company Name	(Seed Money)	Inv. #	Date Paid	22-Aug-01	Inv. #	Date Paid	9-Jan-02	Inv. #	Date Paid	27-Aug-02	Inv. #	Date Paid	23-Sep-03	Inv. #	Date Paid	TOTAL
3	BP	\$15,000	522922	8-Nov-00	\$768,941	529301	4-Oct-01	\$806,441	532263	22-Feb-02	\$1,344,069	535033	11-Oct-02	\$1,431,041.00	544951	4-Dec-03	
4		\$22,500	528453	19-Jun-01							\$112,008		2-Oct-02				\$4,500,000
5																	
6	ChevronTexaco	\$15,000	522923	7-Nov-00	\$522,627	529302	9-Oct-01	\$537,627	532244	22-Feb-02	\$896,046	535034	5-Nov-02	\$1,028,700.00	544953	19-Nov-03	\$3,000,000
7																	
8	ConocoPhillips	\$15,000	522924	31-Oct-00	\$246,314	529309	17-Sep-01	\$268,814	532245	16-Jan-02	\$448,023	535035	26-Sep-02	\$514,349.00	544954	27-Oct-03	\$1,500,000
9		\$7,500	528574	31-Jul-01													
10																	
11	ExxonMobil	\$0	523540					\$1,612,882	532246		\$1,344,069	535036	13-Sep-02	\$1,543,049.00	544956		\$3,728,476
12								\$806,441		23-Jan-02				\$771,524.50		3-Oct-03	
13								\$806,441		11-Feb-02							
14																	
15	Shell	\$15,000	523054	24-Oct-00	\$507,627	529305	25-Sep-01	\$537,627	532247	7-Feb-02	\$896,046	535037		\$1,028,700.00	544958		
16		\$15,000	528333	15-May-01							\$448,023		25-Sep-02	\$514,350		28 Oct 03	\$3,000,000
17											\$448,023		10-Feb-03	\$514,350		14 Jan 04	
18	Marathon	\$15,000	528541	14-Aug-01								Marathon Ashland		\$150,000	548582	20-Jan-04	\$215,000
19												Marathon Oil		\$50,000	548581	3-Feb-04	
20																	
21	Total	\$120,000			\$2,045,509			\$5,376,273			\$5,936,307			\$7,546,063.50			\$15,943,476
22																	
23	LT 4/7/04																

Benzene Health Research Consortium
Sponsor Payment Detail 4Q03 Financial Report

	A	B	C	D	E
1	ID	CompanyName	PaymentDate	PaymentAmount	TOTALS
2	19982	Shell Chemical	10/24/2000	\$ 15,000.00	
3	20086	ConocoPhillips	10/31/2000	\$ 15,000.00	
4	20972	ChevronTexaco	11/7/2000	\$ 15,000.00	yr 2000
5	20239	BP International Limited	11/8/2000	\$ 15,000.00	\$ 60,000.00
6	28285	Shell Chemical	5/15/2001	\$ 15,000.00	
7	28929	BP International Ltd	6/19/2001	\$ 22,500.00	
8	29861	ConocoPhillips	7/31/2001	\$ 7,500.00	
9	30179	Marathon Ashland Petroleum, LLC.	8/14/2001	\$ 15,000.00	yr 2001
10	30853	ConocoPhillips	9/17/2001	\$ 246,314.00	\$ 2,105,509.00
11	31000	Shell Chemical	9/25/2001	\$ 507,627.00	
12	31141	BP p.l.c.	10/4/2001	\$ 768,941.00	
13	31179	ChevronTexaco	10/9/2001	\$ 522,627.00	
14	33206	ConocoPhillips	1/16/2002	\$ 268,814.00	
15	34334	ExxonMobil Research and Engineering	1/23/2002	\$ 806,441.00	
16	34823	Shell Chemical	2/7/2002	\$ 537,627.00	yr 2002
17	34889	ExxonMobil Research and Engineering	2/11/2002	\$ 806,441.00	\$ 8,355,629.00
18	35200	ChevronTexaco	2/22/2002	\$ 537,627.00	
19	35207	BP p.l.c.	2/22/2002	\$ 806,441.00	
20	38625	ExxonMobil	9/13/2002	\$ 1,344,069.00	
21	38748	Shell Chemical	9/25/2002	\$ 448,023.00	
22	38779	ConocoPhillips	9/26/2002	\$ 448,023.00	
23	39101	BP p.l.c.	10/2/2002	\$ 112,008.00	
24	39214	BP p.l.c.	10/11/2002	\$ 1,344,069.00	1+2Q03
25	39493	ChevronTexaco	11/5/2002	\$ 896,046.00	\$ 448,024.09
26	44094	Shell Chemical	2/10/2003	\$ 448,023.00	3Q03
27	51153	ExxonMobil	10/3/2003	\$ 771,524.50	-0-
28	51869	ConocoPhillips	10/27/2003	\$ 514,349.00	4Q03
29	51891	Shell Chemical	10/28/2003	\$ 514,350.00	\$ 4,259,964.50
30	52332	ChevronTexaco	11/19/2003	\$ 1,028,700.00	\$ 15,229,126.59
31	52633	BP p.l.c.	12/4/2003	\$ 1,431,041.00	
32	42934	American Petroleum Institute	1/17/2003	\$ 1.09	
33					
34				\$ 15,229,126.59	
35			(note - does not include interst income)		
36					
37	LT 4/7/04				